Art. -Nr.: HY-13637

Ganciclovir

(Synonyms: BW 759; 2'-Nor-2'-deoxyguanosine)

28 Cited Publications

Kundenbewertung

Based on 28 publication(s) in Google Scholar

Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC₅₀ of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.89%
CAS. Nr.: 82410-32-0
Formel: C₉H₁₃N₅O₄
Molecular Weight:255.23

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Ganciclovir Chemical Structure

CAS. Nr.: 82410-32-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (28)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]^[3]

CMV

HSV-1

HSV-2

FHV-1

5.2 μM (IC₅₀)

Alle HSV Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BC-3	IC₅₀	70 μM Compound: GCV	Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay	[PMID: 17402726]
BJ	EC₅₀	3 μM Compound: GCV	Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days	[PMID: 18458124]
Bone marrow cell	CC₅₀	30 μM Compound: ganciclovir	Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days	[PMID: 17329103]
BSC-1	IC₅₀	3.5 μM Compound: Ganciclovir	Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells	[PMID: 10882370]
BSC-1	IC₅₀	3.5 μM Compound: Ganciclovir	ELISA assay was performed using BSC-1 cells to determine activity against HSV-1 ELISA assay was performed using BSC-1 cells to determine activity against HSV-1	[PMID: 10882372]
BSC-1	IC₅₀	3.5 μM Compound: GCV (ganciclovir) (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509174]
BSC-1	IC₅₀	3.5 μM Compound: GCV (ganciclovir) (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509175]
BSC-1	IC₅₀	3.5 μM Compound: GCV (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509176]
BSC-1	IC₅₀	>100 μM Compound: Ganciclovir	Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells). Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).	[PMID: 2175356]
BSC-1	IC₅₀	>100 μM Compound: Ganciclovir (DHPG)	Cytotoxicity against Monkey kidney cells(BSC-1 cells) Cytotoxicity against Monkey kidney cells(BSC-1 cells)	[PMID: 2500527]
BSC-1	IC₅₀	>100 μM Compound: ganciclovir	The compound was tested for cytotoxicity against BSC1 cell The compound was tested for cytotoxicity against BSC1 cell	[PMID: 2840500]
BSC-1	IC₅₀	3 μM Compound: Ganciclovir	Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells	[PMID: 2913300]
BSC-1	IC₅₀	3.5 μM Compound: 1	In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells. In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells.	[PMID: 9057865]
carcinoma cell line	IC₅₀	>100 μM Compound: Ganciclovir	Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay. Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.	[PMID: 10882375]
CCRF-CEM	IC₅₀	>390 μM Compound: Ganciclovir	In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity	[PMID: 11814776]
CCRF-CEM	CC₅₀	>200 μM Compound: Ganciclovir	Compound concentration required to reduce viability of CEM cells Compound concentration required to reduce viability of CEM cells	[PMID: 14643328]
CCRF-CEM	EC₅₀	>200 μM Compound: Ganciclovir	Compound was tested for anti-viral activity against HIV-1 in CEM cells Compound was tested for anti-viral activity against HIV-1 in CEM cells	[PMID: 14643328]
CCRF-CEM	EC₅₀	>200 μM Compound: Ganciclovir	Compound was tested for anti-viral activity against HIV-2 in CEM cells Compound was tested for anti-viral activity against HIV-2 in CEM cells	[PMID: 14643328]
CCRF-CEM	CC₅₀	5 μM Compound: ganciclovir	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	[PMID: 15615545]
CCRF-CEM	EC₅₀	>50 μM Compound: Gancyclovir	Antiviral activity against HIV1 IIIB in CEM cells Antiviral activity against HIV1 IIIB in CEM cells	[PMID: 16392791]
CCRF-CEM	EC₅₀	>50 μM Compound: Gancyclovir	Antiviral activity against HIV2 ROD in CEM cells Antiviral activity against HIV2 ROD in CEM cells	[PMID: 16392791]
CCRF-CEM	CC₅₀	>100 μM Compound: 1	Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method	[PMID: 28829913]
CCRF-HSB-2	IC₅₀	17 μg/mL Compound: DHPG	Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.	[PMID: 9216836]
CFU-GM	IC₅₀	19 μM Compound: Ganciclovir	In vitro toxicity against colony forming unit granulocyte macrophage (CFU-GM) In vitro toxicity against colony forming unit granulocyte macrophage (CFU-GM)	[PMID: 8176714]
DG-75	IC₅₀	>100 μM Compound: GCV	Cytotoxicity against DG75 cells after 120 hrs by MTT assay Cytotoxicity against DG75 cells after 120 hrs by MTT assay	[PMID: 17402726]
E6SM	EC₅₀	>100 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	0.0012 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	0.0012 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	>100 μg/mL Compound: Ganciclovir	Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	>100 μg/mL Compound: Ganciclovir	Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.019 μg/mL Compound: Ganciclovir	Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.019 μg/mL Compound: Ganciclovir	Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.019 μg/mL Compound: Ganciclovir	Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.019 μg/mL Compound: Ganciclovir	Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.019 μg/mL Compound: Ganciclovir	Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.032 μg/mL Compound: Ganciclovir	Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	2.4 μg/mL Compound: Ganciclovir	Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	>100 μg/mL Compound: ganciclovir	Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	0.003 μg/mL Compound: ganciclovir	Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	0.004 μg/mL Compound: ganciclovir	Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	2.4 μg/mL Compound: ganciclovir	Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	>100 μg/mL Compound: ganciclovir	Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	0.002 μg/mL Compound: ganciclovir	Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	0.007 μg/mL Compound: ganciclovir	Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	0.02 μg/mL Compound: ganciclovir	Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	0.7 μg/mL Compound: ganciclovir	Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	CC₅₀	>100 μg/mL Compound: ganciclovir	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells	[PMID: 8709116]
Fibroblast	IC₅₀	156 μM Compound: GCV	Inhibitory activity against human foreskin fibroblast cell proliferation Inhibitory activity against human foreskin fibroblast cell proliferation	[PMID: 11708924]
Fibroblast	EC₅₀	0.04 μM Compound: 10	Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 19397271]
Fibroblast	EC₅₀	1.2 μM Compound: 10	Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay	[PMID: 19397271]
Fibroblast	EC₅₀	5.5 μM Compound: 10	Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay	[PMID: 19397271]
Fibroblast	IC₅₀	>100 μM Compound: Ganciclovir (DHPG)	Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells) Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells)	[PMID: 2500527]
Fibroblast	IC₅₀	0.05 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line	[PMID: 2826784]
Fibroblast	IC₅₀	3.4 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line	[PMID: 2826784]
Fibroblast	IC₅₀	168 μM Compound: ganciclovir	Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells	[PMID: 8394933]
HEL	CC₅₀	>50 μg/mL Compound: Ganciclovir	The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells	[PMID: 10197958]
HEL	IC₅₀	>50 μM Compound: DHPG	The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50% The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%	[PMID: 10411487]
HEL	IC₅₀	>50 μM Compound: DHPG	Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells	[PMID: 10411487]
HEL	IC₅₀	1 μM Compound: DHPG	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain	[PMID: 10411487]
HEL	IC₅₀	5 μM Compound: DHPG	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain	[PMID: 10411487]
HEL	CC₅₀	394 μM Compound: ganciclovir	Inhibition of cell growth in HEL cells. Inhibition of cell growth in HEL cells.	[PMID: 10966745]
HEL	EC₅₀	11.8 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines	[PMID: 11495586]
HEL	EC₅₀	7.8 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines	[PMID: 11495586]
HEL	CC₅₀	>50 μg/mL Compound: Ganciclovir	Cytotoxic concentration reducing HEL cell growth by 50%. Cytotoxic concentration reducing HEL cell growth by 50%.	[PMID: 12217359]
HEL	CC₅₀	>400 μM Compound: Ganciclovir	Compound concentration required to reduce viability of HEL cells Compound concentration required to reduce viability of HEL cells	[PMID: 14643328]
HEL	EC₅₀	0.06 μM Compound: Ganciclovir	Compound was tested for anti-viral activity against HSV-1(G) in HEL cells Compound was tested for anti-viral activity against HSV-1(G) in HEL cells	[PMID: 14643328]
HEL	CC₅₀	>150 μM Compound: Ganciclovir	Concentration required against HEL cell proliferation Concentration required against HEL cell proliferation	[PMID: 14643358]
HEL	CC₅₀	>150 μM Compound: Ganciclovir	Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4 Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4	[PMID: 15027877]
HEL	EC₅₀	2.7 μM Compound: Ganciclovir	Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection	[PMID: 15027877]
HEL	EC₅₀	3.9 μM Compound: Ganciclovir	Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection	[PMID: 15027877]
HEL	CC₅₀	>150 μM Compound: DHPG(ganciclovir)	Cytotoxic concentration required to reduce HEL cell growth by 50% Cytotoxic concentration required to reduce HEL cell growth by 50%	[PMID: 15081019]
HEL	EC₅₀	0.8 μM Compound: DHPG(ganciclovir)	Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures	[PMID: 15081019]
HEL	EC₅₀	0.9 μM Compound: DHPG(ganciclovir)	Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures	[PMID: 15081019]
HEL	CC₅₀	>150 μM Compound: ganciclovir	Cytotoxic concentration required to reduce HEL cell growth by 50% Cytotoxic concentration required to reduce HEL cell growth by 50%	[PMID: 15481985]
HEL	EC₅₀	0.5 μM Compound: ganciclovir	Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	1.5 μM Compound: ganciclovir	Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	0.06 μM Compound: Gancyclovir	Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells	[PMID: 15658858]
HEL	CC₅₀	65.4 μg/mL Compound: GCV (Ganciclovir)	Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells	[PMID: 15658861]
HEL	EC₅₀	0.37 μg/mL Compound: Ganciclovir	Effective concentration against AD-169 strain of CMV virus expressed in HEL cells Effective concentration against AD-169 strain of CMV virus expressed in HEL cells	[PMID: 15689173]
HEL	EC₅₀	0.37 μg/mL Compound: Ganciclovir	Effective concentration against Davis strain of CMV virus expressed in HEL cells Effective concentration against Davis strain of CMV virus expressed in HEL cells	[PMID: 15689173]
HEL	IC₅₀	2.7 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line	[PMID: 15745823]
HEL	CC₅₀	>150 μM Compound: Ganciclovir	Cytotoxic concentration required to reduce HEL cell growth Cytotoxic concentration required to reduce HEL cell growth	[PMID: 15801851]
HEL	EC₅₀	1.5 μM Compound: Ganciclovir	Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	1.5 μM Compound: Ganciclovir	Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	0.06 μM Compound: Gancyclovir	Antiviral activity against HSV1 KOS in HEL cells Antiviral activity against HSV1 KOS in HEL cells	[PMID: 16392791]
HEL	EC₅₀	0.06 μM Compound: Gancyclovir	Antiviral activity against HSV2 G in HEL cells Antiviral activity against HSV2 G in HEL cells	[PMID: 16392791]
HEL	CC₅₀	>197 μM Compound: GCV	Cytotoxic activity against cultured human embryonic lung (HEL) cells Cytotoxic activity against cultured human embryonic lung (HEL) cells	[PMID: 16392824]
HEL	CC₅₀	34 μg/mL Compound: ganciclovir	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 16480257]
HEL	CC₅₀	>100 μM Compound: Gancyclovir	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 17181162]
HEL	EC₅₀	>100 μM Compound: Gancyclovir	Antiviral activity against vaccinia virus in HEL cells Antiviral activity against vaccinia virus in HEL cells	[PMID: 17181162]
HEL	EC₅₀	>100 μM Compound: Gancyclovir	Antiviral activity against vesicular somatitis virus in HEL cells Antiviral activity against vesicular somatitis virus in HEL cells	[PMID: 17181162]
HEL	EC₅₀	0.032 μM Compound: Gancyclovir	Antiviral activity against HSV2 in HEL cells Antiviral activity against HSV2 in HEL cells	[PMID: 17181162]
HEL	EC₅₀	0.0014 μg/mL Compound: ganciclovir	Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.0096 μg/mL Compound: ganciclovir	Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.91 μg/mL Compound: ganciclovir	Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	1.5 μg/mL Compound: ganciclovir	Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	1.5 μg/mL Compound: ganciclovir	Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.00038 μg/mL Compound: ganciclovir	Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.38 ng/mL Compound: ganciclovir	Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	2.75 μM Compound: ganciclovir	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation	[PMID: 17518459]
HEL	EC₅₀	6.3 μM Compound: ganciclovir	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation	[PMID: 17518459]
HEL	CC₅₀	172 μM Compound: ganciclovir	Cytotoxicity against HEL cells assessed as cell growth after 7 days Cytotoxicity against HEL cells assessed as cell growth after 7 days	[PMID: 17539622]
HEL	EC₅₀	1.3 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days	[PMID: 17539622]
HEL	EC₅₀	4.8 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days	[PMID: 17539622]
HEL	CC₅₀	87 μg/mL Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as reduction of cell growth Cytotoxicity against human HEL cells assessed as reduction of cell growth	[PMID: 17583388]
HEL	EC₅₀	0.64 μg/mL Compound: Ganciclovir	Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation	[PMID: 17583388]
HEL	EC₅₀	1.9 μg/mL Compound: Ganciclovir	Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation	[PMID: 17583388]
HEL	CC₅₀	>200 μM Compound: GCV	Cytotoxicity against HEL cells after 3 days Cytotoxicity against HEL cells after 3 days	[PMID: 17622128]
HEL	EC₅₀	2.3 μM Compound: GCV	Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	5.1 μM Compound: GCV	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17622128]
HEL	EC₅₀	8.7 μM Compound: GCV	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17622128]
HEL	CC₅₀	262 μM Compound: ganciclovir	Cytotoxicity against human HEL cells assessed as reduction of cell growth Cytotoxicity against human HEL cells assessed as reduction of cell growth	[PMID: 17672445]
HEL	EC₅₀	2.6 μM Compound: ganciclovir	Antiviral activity against CMV Davis in human HEL cells after 7 days Antiviral activity against CMV Davis in human HEL cells after 7 days	[PMID: 17672445]
HEL	EC₅₀	6.5 μM Compound: ganciclovir	Antiviral activity against CMV AD169 in human HEL cells after 7 days Antiviral activity against CMV AD169 in human HEL cells after 7 days	[PMID: 17672445]
HEL	CC₅₀	146 μg/mL Compound: ganciclovir	Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days	[PMID: 17869124]
HEL	EC₅₀	0.51 μg/mL Compound: ganciclovir	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17869124]
HEL	EC₅₀	0.8 μg/mL Compound: ganciclovir	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17869124]
HEL	CC₅₀	122 μg/mL Compound: gancyclovir	Cytotoxicity against HEL cells assessed as cell growth after 3 days Cytotoxicity against HEL cells assessed as cell growth after 3 days	[PMID: 17948980]
HEL	EC₅₀	0.0014 μg/mL Compound: gancyclovir	Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.0036 μg/mL Compound: gancyclovir	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.9 μg/mL Compound: gancyclovir	Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	1.29 μg/mL Compound: gancyclovir	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	1.68 μg/mL Compound: gancyclovir	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.00056 μg/mL Compound: gancyclovir	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.56 ng/mL Compound: gancyclovir	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	CC₅₀	172 μM Compound: ganciclovir	Cytotoxicity against HEL cells assessed as reduction in cell growth Cytotoxicity against HEL cells assessed as reduction in cell growth	[PMID: 17961851]
HEL	EC₅₀	1.3 μM Compound: ganciclovir	Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	[PMID: 17961851]
HEL	EC₅₀	4.8 μM Compound: ganciclovir	Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	[PMID: 17961851]
HEL	EC₅₀	0.54 μg/mL Compound: GCV	Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	1.5 μg/mL Compound: GCV	Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	4.9 μg/mL Compound: GCV	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	6 μg/mL Compound: GCV	Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	6.2 μg/mL Compound: GCV	Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	7.6 μg/mL Compound: GCV	Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	9.1 μg/mL Compound: GCV	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	9.4 μg/mL Compound: GCV	Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	CC₅₀	146 μg/mL Compound: ganciclovir	Cytotoxicity against HEL cells assessed as reduction of growth after 3 days Cytotoxicity against HEL cells assessed as reduction of growth after 3 days	[PMID: 18835175]
HEL	EC₅₀	0.51 μg/mL Compound: ganciclovir	Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity	[PMID: 18835175]
HEL	EC₅₀	0.8 μg/mL Compound: ganciclovir	Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity	[PMID: 18835175]
HEL	EC₅₀	>100 μg/mL Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	>100 μg/mL Compound: Ganciclovir	Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	0.06 μg/mL Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	0.06 μg/mL Compound: Ganciclovir	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	1 μg/mL Compound: Ganciclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	CC₅₀	134 μM Compound: GCV, ganciclovir	Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days	[PMID: 19226140]
HEL	EC₅₀	0.66 μM Compound: GCV, ganciclovir	Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.69 μM Compound: GCV, ganciclovir	Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.7 μM Compound: GCV, ganciclovir	Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	1.2 μM Compound: GCV, ganciclovir	Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	2 μM Compound: GCV, ganciclovir	Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection	[PMID: 19226140]
HEL	EC₅₀	2.6 μM Compound: GCV, ganciclovir	Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	3.5 μM Compound: GCV, ganciclovir	Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	3.6 μM Compound: GCV, ganciclovir	Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection	[PMID: 19226140]
HEL	EC₅₀	4 μM Compound: GCV, ganciclovir	Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	4.3 μM Compound: GCV, ganciclovir	Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	>100 μM Compound: GCV	Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	>100 μM Compound: GCV	Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	0.02 μM Compound: GCV	Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	0.2 μM Compound: GCV	Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	9 μM Compound: GCV	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	CC₅₀	400 μg/mL Compound: Ganciclovir	Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology	[PMID: 19324473]
HEL	CC₅₀	80 μg/mL Compound: Ganciclovir	Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth	[PMID: 19324473]
HEL	EC₅₀	1 μg/mL Compound: Ganciclovir	Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation	[PMID: 19324473]
HEL	EC₅₀	1.4 μg/mL Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation	[PMID: 19324473]
HEL	EC₅₀	1.7 μg/mL Compound: Ganciclovir	Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation	[PMID: 19324473]
HEL	EC₅₀	15 μg/mL Compound: Ganciclovir	Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation	[PMID: 19324473]
HEL	CC₅₀	221 μM Compound: 1b, GCV	Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days	[PMID: 19339082]
HEL	EC₅₀	0.59 μM Compound: 1b, GCV	Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	1.1 μM Compound: 1b, GCV	Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	12.6 μM Compound: 1b, GCV	Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection	[PMID: 19339082]
HEL	EC₅₀	2.5 μM Compound: 1b, GCV	Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection	[PMID: 19339082]
HEL	EC₅₀	2.5 μM Compound: 1b, GCV	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	>100 μg/mL Compound: ganciclovir	Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	>100 μg/mL Compound: ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	0.08 μg/mL Compound: ganciclovir	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	0.08 μg/mL Compound: ganciclovir	Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	6 μg/mL Compound: ganciclovir	Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	CC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	>100 μg/mL Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	>100 μg/mL Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	0.05 μg/mL Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	0.07 μg/mL Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	2 μg/mL Compound: Ganciclovir	Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	CC₅₀	1077 μM Compound: Ganciclovir	Cytotoxicity against HEL Cytotoxicity against HEL	[PMID: 20809641]
HEL	EC₅₀	>100 μg/mL Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	>100 μg/mL Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	0.03 μg/mL Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	0.03 μg/mL Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	58 μg/mL Compound: Ganciclovir	Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	CC₅₀	164 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells after 3 days Cytotoxicity against human HEL cells after 3 days	[PMID: 21128666]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	0.05 μM Compound: Ganciclovir	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	0.08 μM Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	3 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	5.2 μM Compound: Ganciclovir	Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	CC₅₀	>250 μM Compound: Ganciclovir	Cytotoxicity against HEL cells after 3 days by coulter counter analysis Cytotoxicity against HEL cells after 3 days by coulter counter analysis	[PMID: 21232828]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.01 μM Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.04 μM Compound: Ganciclovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.1 μM Compound: Ganciclovir	Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	CC₅₀	435 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter	[PMID: 21565516]
HEL	EC₅₀	>250 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.027 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	15.7 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	6 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	6.54 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	0.8 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	CC₅₀	543 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells after 3 days by coulter counter Cytotoxicity against human HEL cells after 3 days by coulter counter	[PMID: 21745746]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.02 μM Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	1.65 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days	[PMID: 22459876]
HEL	EC₅₀	1.65 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days	[PMID: 22459876]
HEL	EC₅₀	100 μM Compound: Ganciclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	CC₅₀	130 μM Compound: Ganciclovir	Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter	[PMID: 22578783]
HEL	EC₅₀	7.1 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	EC₅₀	7.5 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	CC₅₀	231 μM Compound: Ganciclovir	Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay	[PMID: 22858222]
HEL	EC₅₀	0.027 μM Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	0.029 μM Compound: Ganciclovir	Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	14.7 μM Compound: Ganciclovir	Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	5.9 μM Compound: Ganciclovir	Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	9.1 μM Compound: Ganciclovir	Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	≥93 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	0.013 μM Compound: Ganciclovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	0.015 μM Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	4 μM Compound: Ganciclovir	Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	CC₅₀	200 μM Compound: Ganciclovir	Cytotoxicity against HEL Cytotoxicity against HEL	[PMID: 23743443]
HEL	EC₅₀	0.01 μM Compound: ganciclovir	Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity	[PMID: 23795238]
HEL	EC₅₀	0.01 μM Compound: ganciclovir	Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity	[PMID: 23795238]
HEL	EC₅₀	1 μM Compound: ganciclovir	Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity	[PMID: 23795238]
HEL	EC₅₀	100 μM Compound: ganciclovir	Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity	[PMID: 23795238]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	4 μM Compound: Ganciclovir	Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	5.98 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation	[PMID: 23811093]
HEL	EC₅₀	7.87 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation	[PMID: 23811093]
HEL	CC₅₀	>350 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells after 3 days by Coulter counting method Cytotoxicity against human HEL cells after 3 days by Coulter counting method	[PMID: 23911854]
HEL	EC₅₀	8.2 μM Compound: Ganciclovir	Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after	[PMID: 23911854]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	0.38 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation	[PMID: 23911856]
HEL	EC₅₀	0.9 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	3.1 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation	[PMID: 23911856]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	0.02 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	0.5 μM Compound: Ganciclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	6.3 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	7.1 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	CC₅₀	328.5 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days	[PMID: 26291038]
HEL	EC₅₀	4.72 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy	[PMID: 26291038]
HEL	EC₅₀	6.12 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy	[PMID: 26291038]
HEL	EC₅₀	13.9 μM Compound: GCV	Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation	[PMID: 26443550]
HEL	EC₅₀	7.8 μM Compound: GCV	Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation	[PMID: 26443550]
HEL	CC₅₀	≥319 μM Compound: GCV	Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method	[PMID: 26443550]
HEL	EC₅₀	0.25 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD169 infected in HEL cells Antiviral activity against Cytomegalovirus AD169 infected in HEL cells	[PMID: 27128178]
HEL	EC₅₀	0.4 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells	[PMID: 27128178]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	0.09 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	100 μM Compound: Ganciclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	2.1 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	3.1 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	CC₅₀	>350 μM Compound: Ganciclovir	Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition	[PMID: 27750154]
HEL	CC₅₀	>391 μM Compound: Ganciclovir	Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method	[PMID: 28682067]
HEL	CC₅₀	308 μM Compound: Ganciclovir	Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method	[PMID: 28757102]
HEL	CC₅₀	273 μM Compound: 1	Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method	[PMID: 28829913]
HEL	CC₅₀	>350 μM Compound: Ganciclovir	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29407990]
HEL	CC₅₀	>391 μM Compound: Ganciclovir	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29550734]
HEL	CC₅₀	>319 μM Compound: Ganciclovir	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29670705]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	0.07 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	0.09 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	≥20 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	CC₅₀	>394 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method	[PMID: 32676147]
HEL	EC₅₀	13 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days	[PMID: 32676147]
HEL	EC₅₀	4.44 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days	[PMID: 32676147]
HEL	CC₅₀	231.22 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis	[PMID: 33479570]
HEL	CC₅₀	>300 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	[PMID: 33894564]
HEL	CC₅₀	130 μM Compound: Ganciclovir	Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs	[PMID: 38643669]
HEL	IC₅₀	0.5 μM Compound: ganciclovir	Inhibition of human CMV DNA synthesis in CMV-infected HEL cells. Inhibition of human CMV DNA synthesis in CMV-infected HEL cells.	[PMID: 7752205]
HEL	IC₅₀	7 μM Compound: ganciclovir	Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR. Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR.	[PMID: 7752205]
HEL	CC₅₀	>200 μg/mL Compound: GCV	Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells. Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.	[PMID: 7877148]
HEL	IC₅₀	0.02 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	0.072 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%	[PMID: 7877148]
HEL	IC₅₀	0.1 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	0.9 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	2.9 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	6.2 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.	[PMID: 7877148]
HEL	ED₅₀	0.016 μg/mL Compound: DHPG	Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells. Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	0.039 μg/mL Compound: DHPG	Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells. Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	0.21 μg/mL Compound: DHPG	Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells. Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	0.21 μg/mL Compound: DHPG	Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells. Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	IC₅₀	0.5 μg/mL Compound: ganciclovir	Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells	[PMID: 9836626]
HEL	IC₅₀	0.5 μg/mL Compound: ganciclovir	Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells	[PMID: 9836626]
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	>100 μM Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	0.08 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	0.08 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	6 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	CC₅₀	60.5 μg/mL Compound: Ganciclovir	Cytotoxicity against HEL Cytotoxicity against HEL	10.1007/s00044-011-9776-0
HEL	EC₅₀	1.79 μg/mL Compound: Ganciclovir	Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation	10.1007/s00044-011-9776-0
HEL	EC₅₀	2.68 μg/mL Compound: Ganciclovir	Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation	10.1007/s00044-011-9776-0
HEL	CC₅₀	200 μg/mL Compound: 11) 2 (Ganciclovir GCV)	Cytotoxicity (to reduce cell growth) against Cytomegalovirus in human embryonic lung (HEL) cells Cytotoxicity (to reduce cell growth) against Cytomegalovirus in human embryonic lung (HEL) cells	10.1016/S0960-894X(01)80538-2
HEL	IC₅₀	1.5 μg/mL Compound: 11) 2 (Ganciclovir GCV)	Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells	10.1016/S0960-894X(01)80538-2
HEL	IC₅₀	2 μg/mL Compound: 11) 2 (Ganciclovir GCV)	Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells	10.1016/S0960-894X(01)80538-2
HEL	IC₅₀	1.2 μg/mL Compound: Ganciclovir	Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells	10.1016/S0960-894X(97)00149-2
HEL	IC₅₀	1.3 μg/mL Compound: Ganciclovir	Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells	10.1016/S0960-894X(97)00149-2
HEL 299	CC₅₀	>10 μg/mL Compound: GCV	Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay	[PMID: 11262090]
HEL 299	CC₅₀	>333 μM Compound: GCV, Ganciclovir	Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay	[PMID: 20047911]
HEL 299	EC₅₀	2.39 μM Compound: GCV, Ganciclovir	Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay	[PMID: 20047911]
HEL 299	CC₅₀	>100 μM Compound: 1b	Cytotoxicity against human HEL299 cells after 3 days by MTT assay Cytotoxicity against human HEL299 cells after 3 days by MTT assay	[PMID: 26460883]
HEL 299	CC₅₀	>50 μM Compound: GCV	Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay	[PMID: 34147908]
HEL 299	CC₅₀	>100 μM Compound: ganciclovir	In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay. In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay.	[PMID: 9925738]
HEL 299	EC₅₀	0.63 μM Compound: ganciclovir	In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay. In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay.	[PMID: 9925738]
HEL 299	CC₅₀	>400 μg/mL Compound: ganciclovir	Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay	10.1016/S0960-894X(00)80078-5
HeLa	EC₅₀	>100 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines	[PMID: 11495586]
HeLa	CC₅₀	>50 μg/mL Compound: Ganciclovir	Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology	[PMID: 19324473]
HeLa	CC₅₀	190 μg/mL Compound: Ganciclovir	Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth	[PMID: 19324473]
HeLa	CC₅₀	221.8 μM Compound: Ganciclovir	Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
HeLa	CC₅₀	>50 μg/mL Compound: Ganciclovir	Cytotoxic activity was measured in human embryonic lung cells (HeLa) Cytotoxic activity was measured in human embryonic lung cells (HeLa)	10.1016/S0960-894X(97)00149-2
HEp-2	EC₅₀	26.7 μg/mL Compound: gancyclovir	Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay	[PMID: 9599250]
HEp-2	EC₅₀	5 μg/mL Compound: gancyclovir	Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	>100 μg/mL Compound: gancyclovir	Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	840 μg/mL Compound: gancyclovir	Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days	[PMID: 9599250]
Hepatocyte	EC₅₀	1.5 μg/mL Compound: GCV, Ganciclovir	Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures	[PMID: 11985471]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration	[PMID: 10882370]
HFF	IC₅₀	7.4 μM Compound: Ganciclovir	Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells	[PMID: 10882370]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration	[PMID: 10882372]
HFF	IC₅₀	7.4 μM Compound: Ganciclovir	Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells	[PMID: 10882372]
HFF	IC₅₀	>100 μM Compound: 1, Gancyclovir	Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration	[PMID: 10882374]
HFF	IC₅₀	4.1 μM Compound: 1, Gancyclovir	Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	4.5 μM Compound: 1, Gancyclovir	Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	7.4 μM Compound: 1, Gancyclovir	Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells	[PMID: 10882375]
HFF	IC₅₀	7.4 μM Compound: Ganciclovir	Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells	[PMID: 10882375]
HFF	IC₅₀	0.6 μM Compound: Ganciclovir	Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV	[PMID: 10999475]
HFF	CC₅₀	>100 μM Compound: Ganciclovir	In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line	[PMID: 14736238]
HFF	CC₅₀	>392 μM Compound: Ganciclovir	In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line	[PMID: 14736238]
HFF	EC₅₀	2.3 μM Compound: Ganciclovir	In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line	[PMID: 14736238]
HFF	EC₅₀	4.1 μM Compound: Ganciclovir	In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line	[PMID: 14736238]
HFF	IC₅₀	>100 μM Compound: GCV	Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination	[PMID: 15509173]
HFF	IC₅₀	>100 μM Compound: GCV (ganciclovir) (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509174]
HFF	IC₅₀	7.4 μM Compound: GCV (ganciclovir) (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509174]
HFF	IC₅₀	>100 μM Compound: GCV (ganciclovir) (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509175]
HFF	IC₅₀	7.4 μM Compound: GCV (ganciclovir) (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509175]
HFF	IC₅₀	>100 μM Compound: GCV (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509176]
HFF	IC₅₀	1.2 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	1.2 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	1.2 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	2.5 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	7.4 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	CC₅₀	>100 μM Compound: ganciclovir	Cytotoxicity against HFF cells by visual cytotoxicity Cytotoxicity against HFF cells by visual cytotoxicity	[PMID: 15615545]
HFF	CC₅₀	>392 μM Compound: ganciclovir	Cytotoxicity against HFF cells by neutral red uptake assay Cytotoxicity against HFF cells by neutral red uptake assay	[PMID: 15615545]
HFF	EC₅₀	2.1 μM Compound: ganciclovir	Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay	[PMID: 15615545]
HFF	EC₅₀	2.2 μM Compound: ganciclovir	Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay	[PMID: 15615545]
HFF	CC₅₀	>100 μM Compound: Ganciclovir	Cytotoxic concentration against town strain of human cytomegalovirus infected HFF cells of human (visual cytotoxicity) Cytotoxic concentration against town strain of human cytomegalovirus infected HFF cells of human (visual cytotoxicity)	[PMID: 15634003]
HFF	CC₅₀	>392 μM Compound: Ganciclovir	Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake) Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake)	[PMID: 15634003]
HFF	CC₅₀	>100 μM Compound: ganciclovir	Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay	[PMID: 16134946]
HFF	IC₅₀	0.8 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
HFF	IC₅₀	0.8 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
HFF	IC₅₀	1.3 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO	[PMID: 16134946]
HFF	IC₅₀	>100 μM Compound: gcv	Cytotoxicity against HFF cells Cytotoxicity against HFF cells	[PMID: 16814545]
HFF	CC₅₀	>100 μM Compound: ganciclovir	Cytotoxicity against HFF cell by neutral red uptake assay Cytotoxicity against HFF cell by neutral red uptake assay	[PMID: 17004726]
HFF	EC₅₀	0.15 μM Compound: ganciclovir	Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay	[PMID: 17004726]
HFF	EC₅₀	1.8 μM Compound: ganciclovir	Inhibition of HCMV towne replication in HFF cells by plaque reduction assay Inhibition of HCMV towne replication in HFF cells by plaque reduction assay	[PMID: 17004726]
HFF	IC₅₀	1.3 μM Compound: GCV	Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	1.4 μM Compound: GCV	Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	1.4 μM Compound: GCV	Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	1.9 μM Compound: GCV	Antiviral activity against Human CMV AD169 in HFF cells by PRA Antiviral activity against Human CMV AD169 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	10 μM Compound: GCV	Antiviral activity against Human CMV T2293 in HFF cells by PRA Antiviral activity against Human CMV T2293 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	12.4 μM Compound: GCV	Antiviral activity against Human CMV T2311 in HFF cells by PRA Antiviral activity against Human CMV T2311 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	30.2 μM Compound: GCV	Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	4.1 μM Compound: GCV	Antiviral activity against Human CMV T2291 in HFF cells by PRA Antiviral activity against Human CMV T2291 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	5.6 μM Compound: GCV	Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	7.1 μM Compound: GCV	Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	3 μM Compound: ganciclovir	Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay	[PMID: 17161946]
HFF	CC₅₀	>100 μM Compound: ganciclovir	Cytotoxicity against HFF cells by alamar blue assay Cytotoxicity against HFF cells by alamar blue assay	[PMID: 17329103]
HFF	IC₅₀	1 μM Compound: ganciclovir	Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay	[PMID: 17329103]
HFF	CC₅₀	>100 μM Compound: ganciclovir	Cytotoxicity against HFF cells after 3 days Cytotoxicity against HFF cells after 3 days	[PMID: 17434304]
HFF	IC₅₀	1300 nM Compound: ganciclovir	Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay	[PMID: 17434304]
HFF	EC₅₀	1.1 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	2.6 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	2.7 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	3.5 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	3.9 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	6.1 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	6.6 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	8.4 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	CC₅₀	>100 μM Compound: 14	Cytotoxicity against HFF cells Cytotoxicity against HFF cells	[PMID: 18082410]
HFF	EC₅₀	2.5 μM Compound: 14	Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay	[PMID: 18082410]
HFF	CC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay	[PMID: 18595689]
HFF	IC₅₀	16.4 μM Compound: GCV	Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay	[PMID: 19010684]
HFF	IC₅₀	3.22 μM Compound: GCV	Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay	[PMID: 19010684]
HFF	CC₅₀	550 μM Compound: GCV	Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay	[PMID: 19015358]
HFF	CC₅₀	>100 μM Compound: 10	Cytotoxicity against HFF cells by neutral red uptake assay Cytotoxicity against HFF cells by neutral red uptake assay	[PMID: 19397271]
HFF	CC₅₀	>100 μM Compound: 10	Cytotoxicity against HFF cells by plaque reduction assay Cytotoxicity against HFF cells by plaque reduction assay	[PMID: 19397271]
HFF	IC₅₀	1300 nM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay	[PMID: 20167488]
HFF	CC₅₀	550 μM Compound: GCV	Cytotoxicity against human HFF by MTT assay Cytotoxicity against human HFF by MTT assay	[PMID: 20194695]
HFF	CC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay	[PMID: 20403696]
HFF	IC₅₀	1.3 μM Compound: Ganciclovir	Inhibition of HCMV DNA polymerase infected in HFF cells Inhibition of HCMV DNA polymerase infected in HFF cells	[PMID: 20403696]
HFF	CC₅₀	>100 μM Compound: GCV	Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay	[PMID: 21376429]
HFF	EC₅₀	0.04 μM Compound: GCV	Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay	[PMID: 21376429]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells. Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells.	[PMID: 2163453]
HFF	IC₅₀	>100 μM Compound: ganciclovir (DHPG)	Compound was evaluated for cytotoxic activity against HFF cells Compound was evaluated for cytotoxic activity against HFF cells	[PMID: 2163454]
HFF	IC₅₀	3 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days	[PMID: 21641218]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells). Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).	[PMID: 2175356]
HFF	IC₅₀	>100 μM Compound: GCV	Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay	[PMID: 21812420]
HFF	IC₅₀	0.14 μM Compound: GCV	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay	[PMID: 21812420]
HFF	CC₅₀	>300 μM Compound: GCV	Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining	[PMID: 22607883]
HFF	IC₅₀	2.1 μM Compound: GCV	Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay	[PMID: 22607883]
HFF	CC₅₀	>100 μM Compound: ganciclovir	Cytotoxicity against HFF Cytotoxicity against HFF	[PMID: 26260336]
HFF	IC₅₀	>100 μM Compound: ganciclovir	The compound was tested for cytotoxicity against human foreskin fibroblast cell The compound was tested for cytotoxicity against human foreskin fibroblast cell	[PMID: 2840500]
HFF	IC₅₀	>100 μM Compound: Ganciclovir (DHPG)	Cytotoxicity against uninfected human foreskin fibroblast(HFF cells) Cytotoxicity against uninfected human foreskin fibroblast(HFF cells)	[PMID: 2846837]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity was evaluated against the Human diploid cells (HFF) Cytotoxicity was evaluated against the Human diploid cells (HFF)	[PMID: 2913300]
HFF	CC₅₀	>200 μM Compound: GCV	Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay	[PMID: 32191456]
HFF	CC₅₀	>150 μM Compound: Ganciclovir	Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay	[PMID: 34124679]
HFF	CC₅₀	>50 μM Compound: 1; GCV	Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay	[PMID: 35377638]
HFF	CC₅₀	>150 μM Compound: Ganciclovir	Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay	[PMID: 35754374]
HFF	IC₅₀	4.4 μg/mL Compound: DHPG	Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay). Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay).	[PMID: 7562929]
HFF	IC₅₀	52 μg/mL Compound: DHPG	Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay). Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay).	[PMID: 7562929]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration	[PMID: 7562945]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration	[PMID: 7562946]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration. Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration.	[PMID: 7562947]
HFF	IC₅₀	>100 μM Compound: ganciclovir	Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration	[PMID: 8071942]
HFF	IC₅₀	>100 μM Compound: ganciclovir	Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration	[PMID: 8254613]
HFF	EC₅₀	0.5 μM Compound: ganciclovir	Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells	[PMID: 8394933]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Visual cytotoxicity of compound on HFF cells at time of HCMV plaque enumeration Visual cytotoxicity of compound on HFF cells at time of HCMV plaque enumeration	[PMID: 8632412]
HFF	IC₅₀	>100 μM Compound: Ganciclovir (GCV)	Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection. Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.	[PMID: 8784444]
HFF	IC₅₀	>100 μM Compound: ganciclovir	Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay. Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.	[PMID: 8784445]
HFF	IC₅₀	>100 μM Compound: 1	Visual cytotoxicity was scored on Human foreskin fibroblasts (HFF cells) at the time of plaque enumeration. Visual cytotoxicity was scored on Human foreskin fibroblasts (HFF cells) at the time of plaque enumeration.	[PMID: 9057865]
HFF	IC₅₀	7.4 μM Compound: 1	In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells. In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells.	[PMID: 9057865]
HFF	IC₅₀	>100 μM Compound: Ganciclovir (DHPG)	Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment) Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment)	[PMID: 9057866]
HFF	IC₅₀	7.7 μM Compound: Ganciclovir (DHPG)	Antiviral activity was determined by the HCMV plaque assay using HFF cells Antiviral activity was determined by the HCMV plaque assay using HFF cells	[PMID: 9057866]
HFF	IC₅₀	>100 μM Compound: Ganciclovir (DHPG)	Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration	[PMID: 9057867]
HFF	IC₅₀	>100 μM Compound: Ganciclovir(DHPG)	Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration	[PMID: 9057868]
HFF	IC₅₀	2.6 μM Compound: Ganciclovir	Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay	[PMID: 9438017]
HFF	IC₅₀	7.4 μM Compound: Ganciclovir	Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay	[PMID: 9438017]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity for the compound was determined in uninfected stationary human foreskin fibroblasts (HFF) cells. Cytotoxicity for the compound was determined in uninfected stationary human foreskin fibroblasts (HFF) cells.	[PMID: 9548814]
HFF	IC₅₀	>100 μM Compound: Ganciclovir	Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration. Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration.	[PMID: 9575044]
HFF	IC₅₀	8.4 μM Compound: Ganciclovir	In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay. In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay.	10.1016/S0960-894X(00)80470-9
HFF	IC₅₀	>100 μM Compound: DHPG	Cytotoxicity against human foreskin fibroblasts (HFF) cells Cytotoxicity against human foreskin fibroblasts (HFF) cells	10.1016/S0960-894X(00)80628-9
HS27	CC₅₀	>333 μM Compound: GCV, Ganciclovir	Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay	[PMID: 20047911]
HS27	EC₅₀	0.32 μM Compound: GCV, Ganciclovir	Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay	[PMID: 20047911]
Hs68	CC₅₀	12.5 μg/mL Compound: ganciclovir	Cytotoxicity in the Hs 68 cell line Cytotoxicity in the Hs 68 cell line	[PMID: 10447945]
Hs68	CC₅₀	12.5 μg/mL Compound: GCV	Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation	[PMID: 10888336]
HSV-2	ED₅₀	3 μg/mL Compound: 2a(GCV)	Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)	[PMID: 2848125]
Jurkat	IC₅₀	>100 μM Compound: gcv	Cytotoxicity against human Jurkat cells Cytotoxicity against human Jurkat cells	[PMID: 16814545]
Jurkat	CC₅₀	>100 μM Compound: ganciclovir	Cytotoxicity against human Jurkat cells by alamar blue assay Cytotoxicity against human Jurkat cells by alamar blue assay	[PMID: 17329103]
KB	IC₅₀	>100 μM Compound: Ganciclovir	Compound was tested for the inhibition of KB cell growth in quadruplicate wells Compound was tested for the inhibition of KB cell growth in quadruplicate wells	[PMID: 10882370]
KB	IC₅₀	>100 μM Compound: Ganciclovir	Inhibition of KB cell growth was determined. Inhibition of KB cell growth was determined.	[PMID: 10882372]
KB	IC₅₀	>100 μM Compound: 1, Gancyclovir	Compound was tested for inhibition of KB cell growth in quadruplicate assay Compound was tested for inhibition of KB cell growth in quadruplicate assay	[PMID: 10882374]
KB	IC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB). Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).	[PMID: 1310744]
KB	IC₅₀	>100 μM Compound: GCV	Concentration required to inhibit KB cell line growth was determined by crystal violet staining method Concentration required to inhibit KB cell line growth was determined by crystal violet staining method	[PMID: 15509173]
KB	IC₅₀	>100 μM Compound: GCV (ganciclovir) (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509174]
KB	IC₅₀	>100 μM Compound: GCV (ganciclovir) (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509175]
KB	IC₅₀	>100 μM Compound: GCV (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509176]
KB	IC₅₀	1 mM Compound: Ganciclovir	Tested for cytotoxic activity against human neoplastic cell line(KB cells). Tested for cytotoxic activity against human neoplastic cell line(KB cells).	[PMID: 2163453]
KB	IC₅₀	>100 μM Compound: Ganciclovir	Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells). Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).	[PMID: 2175356]
KB	IC₅₀	1 mM Compound: Ganciclovir (DHPG)	Cytotoxicity against human neoplastic cell line (KB) Cytotoxicity against human neoplastic cell line (KB)	[PMID: 2500527]
KB	IC₅₀	1 mM Compound: ganciclovir	Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells	[PMID: 2840500]
KB	IC₅₀	1 mM Compound: Ganciclovir	Cytotoxicity was evaluated in Human neoplastic cell line (KB) Cytotoxicity was evaluated in Human neoplastic cell line (KB)	[PMID: 2913300]
KB	IC₅₀	>100 μM Compound: Ganciclovir	Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay	[PMID: 7562945]
KB	IC₅₀	>100 μM Compound: Ganciclovir	cell growth inhibition was determined in KB cells in quadruplicate assays cell growth inhibition was determined in KB cells in quadruplicate assays	[PMID: 7562946]
KB	IC₅₀	>100 μM Compound: Ganciclovir	In vitro inhibition of KB cell proliferation. In vitro inhibition of KB cell proliferation.	[PMID: 7562947]
KB	IC₅₀	>100 μM Compound: ganciclovir	Tested for the inhibition of KB cell growth Tested for the inhibition of KB cell growth	[PMID: 8254613]
KB	IC₅₀	>100 μM Compound: Ganciclovir	Inhibitory activity of compound against KB cell growth [>-indicates IC50/IC90 was not reached at the noted (highest) concentration tested] Inhibitory activity of compound against KB cell growth [>-indicates IC50/IC90 was not reached at the noted (highest) concentration tested]	[PMID: 8632412]
KB	IC₅₀	>320 μM Compound: Ganciclovir (GCV)	Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line. Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line.	[PMID: 8784444]
KB	IC₅₀	>100 μM Compound: ganciclovir	Inhibitory activity against growth of KB cell. Inhibitory activity against growth of KB cell.	[PMID: 8784445]
KB	IC₅₀	>100 μM Compound: 1	In vitro inhibition of KB (human carcinoma) cell growth. In vitro inhibition of KB (human carcinoma) cell growth.	[PMID: 9057865]
KB	IC₅₀	>100 μM Compound: Ganciclovir (DHPG)	Cytotoxicity in KB cells. Cytotoxicity in KB cells.	[PMID: 9057866]
KB	IC₅₀	3.5 μM Compound: Ganciclovir (DHPG)	Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment) Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment)	[PMID: 9057866]
KB	IC₅₀	>100 μM Compound: Ganciclovir (DHPG)	Inhibition of KB cell growth was determined Inhibition of KB cell growth was determined	[PMID: 9057867]
KB	IC₅₀	>100 μM Compound: Ganciclovir(DHPG)	Inhibition of KB cell growth was determined Inhibition of KB cell growth was determined	[PMID: 9057868]
KB	IC₅₀	>100 μM Compound: Ganciclovir	Cytotoxicity for the compound was determined by the inhibition of the growing KB cells. Cytotoxicity for the compound was determined by the inhibition of the growing KB cells.	[PMID: 9548814]
KB	IC₅₀	>100 μM Compound: Ganciclovir	Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth. Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth.	[PMID: 9575044]
MEF	CC₅₀	>35 μM Compound: Ganciclovir	In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line	[PMID: 14736238]
MEF	EC₅₀	5 μM Compound: Ganciclovir	In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line	[PMID: 14736238]
MEF	CC₅₀	>392 μM Compound: Ganciclovir	Cytotoxic concentration against murine cytomegalovirus infected MEF cells Cytotoxic concentration against murine cytomegalovirus infected MEF cells	[PMID: 15634003]
MEF	EC₅₀	0.96 μM Compound: GCV	Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay	[PMID: 32191456]
MEF	IC₅₀	3.4 μM Compound: Ganciclovir	Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay	[PMID: 9438017]
MRC5	CC₅₀	98 μM Compound: ganciclovir	Concentration required to reduce MRC-5 cell growth by 50% Concentration required to reduce MRC-5 cell growth by 50%	[PMID: 10966740]
MRC5	IC₅₀	5.9 μM Compound: ganciclovir	Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells	[PMID: 10966740]
MRC5	IC₅₀	>10 μM Compound: GCV	Inhibitory concentration against Xba F strain of HCMV in MRC5 cells Inhibitory concentration against Xba F strain of HCMV in MRC5 cells	[PMID: 11454465]
MRC5	IC₅₀	1.4 μM Compound: GCV	Inhibitory concentration against Davis strain of HCMV in MRC5 cells Inhibitory concentration against Davis strain of HCMV in MRC5 cells	[PMID: 11454465]
MRC5	IC₅₀	1.5 μM Compound: GCV	Inhibitory concentration against Towne strain of HCMV in MRC5 cells Inhibitory concentration against Towne strain of HCMV in MRC5 cells	[PMID: 11454465]
MRC5	IC₅₀	1.6 μM Compound: GCV	Inhibitory concentration against 2599R strain of HCMV in MRC5 cells Inhibitory concentration against 2599R strain of HCMV in MRC5 cells	[PMID: 11454465]
MRC5	IC₅₀	3 μM Compound: GCV	Inhibitory concentration against AD169 strain of HCMV in MRC5 cells Inhibitory concentration against AD169 strain of HCMV in MRC5 cells	[PMID: 11454465]
MRC5	EC₅₀	9.4 μM Compound: ganciclovir	Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells. Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells.	[PMID: 12723951]
MRC5	IC₅₀	4 μM Compound: ganciclovir	In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain) In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain)	[PMID: 1323678]
MRC5	IC₅₀	1.2 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line	[PMID: 15745823]
MRC5	IC₅₀	2.2 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line	[PMID: 15745823]
MRC5	IC₅₀	7.8 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line	[PMID: 15745823]
MRC5	IC₅₀	8.7 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line	[PMID: 15745823]
MRC5	IC₅₀	30.1 μM Compound: GCV	Antiviral activity against Human CMV T2287 in MRC5 cells by PRA Antiviral activity against Human CMV T2287 in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	4.9 μM Compound: GCV	Antiviral activity against Human CMV Towne in MRC5 cells by PRA Antiviral activity against Human CMV Towne in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	5.4 μM Compound: GCV	Antiviral activity against Human CMV T2296 in MRC5 cells by PRA Antiviral activity against Human CMV T2296 in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	0.91 μM Compound: GCV	Antiviral activity against HCMV in MRC5 cells by plaque reduction assay Antiviral activity against HCMV in MRC5 cells by plaque reduction assay	[PMID: 17239594]
MRC5	IC₅₀	970 μM Compound: GCV	Cytotoxicity against MRC5 cells Cytotoxicity against MRC5 cells	[PMID: 17239594]
MRC5	CC₅₀	>333 μM Compound: GCV, Ganciclovir	Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay	[PMID: 20047911]
MRC5	EC₅₀	1.65 μM Compound: GCV, Ganciclovir	Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay	[PMID: 20047911]
MRC5	ED₅₀	0.4 μg/mL Compound: 2' NDG	In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 0.4-1.6 In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 0.4-1.6	[PMID: 2989523]
MRC5	ED₅₀	1 μg/mL Compound: 2' NDG	In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2 In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2	[PMID: 2989523]
MRC5	CC₅₀	>100 μM Compound: 1	Cytotoxicity against human MRC5 cells by CCK-8 assay Cytotoxicity against human MRC5 cells by CCK-8 assay	[PMID: 37037115]
MRC5	IC₅₀	3.2 μg/mL Compound: DHPG	Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay). Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay).	[PMID: 7562929]
MRC5	IC₅₀	1.7 μM Compound: Ganciclovir	In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay	[PMID: 8176714]
MRC5	IC₅₀	6.3 μM Compound: GCV	Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells	[PMID: 9836613]
MRC5	CC₅₀	>100 μg/mL Compound: Ganciclovir	Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation. Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.	[PMID: 9934471]
MRC5	IC₅₀	2.1 μg/mL Compound: Ganciclovir	Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation. Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.	[PMID: 9934471]
MT4	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method	[PMID: 28829913]
Neoplastic cell line	IC₅₀	>100 μM Compound: ganciclovir (DHPG)	Compound was evaluated for cytotoxic activity against KB cells Compound was evaluated for cytotoxic activity against KB cells	[PMID: 2163454]
NHDF	CC₅₀	>333 μM Compound: GCV, Ganciclovir	Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay	[PMID: 20047911]
NIH3T3	EC₅₀	5.7 μM Compound: GCV	Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay	[PMID: 18458124]
OST	IC₅₀	0.0019 μM Compound: GCV	Cytotoxicity against human OST TK- cells expressing HSV1 TK Cytotoxicity against human OST TK- cells expressing HSV1 TK	[PMID: 17181158]
OST	IC₅₀	0.018 μM Compound: GCV	Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine	[PMID: 17181158]
OST	IC₅₀	0.033 μM Compound: GCV	Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine	[PMID: 17181158]
OST	IC₅₀	0.041 μM Compound: GCV	Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine	[PMID: 17181158]
OST	IC₅₀	0.05 μM Compound: GCV	Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine	[PMID: 17181158]
OST	IC₅₀	0.081 μM Compound: GCV	Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine	[PMID: 17181158]
OST	IC₅₀	0.11 μM Compound: GCV	Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine	[PMID: 17181158]
Osteoclast-like	IC₅₀	30 μM Compound: gcv	Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage	[PMID: 16814545]
RG2	CC₅₀	377 μM Compound: GCV	Cytotoxicity against RG2 cells after 72 hrs by MTT assay Cytotoxicity against RG2 cells after 72 hrs by MTT assay	[PMID: 18800764]
Vero	EC₅₀	0.23 μM Compound: Ganciclovir	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	>50 μM Compound: ganciclovir	Inhibition of HSV1 in Vero cells by plaque reduction assay Inhibition of HSV1 in Vero cells by plaque reduction assay	[PMID: 15615545]
Vero	EC₅₀	>50 μM Compound: ganciclovir	Inhibition of HSV2 in Vero cells by plaque reduction assay Inhibition of HSV2 in Vero cells by plaque reduction assay	[PMID: 15615545]
Vero	IC₅₀	1.22 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line	[PMID: 15745823]
Vero	IC₅₀	1.274 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line	[PMID: 15745823]
Vero	CC₅₀	>100 μM Compound: ganciclovir	Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay	[PMID: 16134946]
Vero	CC₅₀	666 μM Compound: GCV	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	0.7 μM Compound: GCV	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	14.5 μM Compound: GCV	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	19.2 μM Compound: GCV	Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	23.5 μM Compound: GCV	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	0.9 μM Compound: 1b	Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	1.4 μM Compound: 1b	Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	11.1 μM Compound: 1b	Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	2.14 μM Compound: 1b	Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	IC₅₀	0.1 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line	[PMID: 2826784]
Vero	IC₅₀	0.1 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line	[PMID: 2826784]
Vero	IC₅₀	2.8 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line	[PMID: 2826784]
Vero	EC₅₀	0.025 μM Compound: GCV	Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis	[PMID: 31503476]
Vero	EC₅₀	0.04 μM Compound: GCV	Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay	[PMID: 32191456]
Vero	EC₅₀	0.58 μM Compound: GCV	Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay	[PMID: 32191456]

In Vitro

Ganciclovir (BW 759) is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median Ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 μM versus 72 μM for acyclovir^[4].
The primary mechanism of Ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ganciclovir (BW 759) (50 mg/kg; i.p.; twice a day for five injections) significantly decreases white blood cells, red blood cells and platelets in newborn mice, and can diffuse into the brain and the perilymphatic space of the inner ear^[3].
Ganciclovir (1-80 mg/kg; i.h.; daily for 5 days) delays murine cytomegalovirus (MCMV)-induced wasting syndrome and mortality^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Non-inbred Oncins France 1 (OF1) mice and albino rats non-immunized for MCMV^[3]
Dosage:

50 mg/kg
Administration:

Intraperitoneal injection, twice a day for five injections (mice) or 3 days (adult rats) (Pharmacokinetic Study)
Result:

In adult rats, the intracochlear diffusion of Ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of Ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection.
Significantly decreased white blood cells, red blood cells and platelets in newborn mice.

Animal Model:

Female SCID mice inoculated with MCMV^[6]
Dosage:

0, 1, 10, 80 and 160 mg/kg
Administration:

Subcutaneous injection, once daily for 5 days
Result:

Dose dependently delayed the wasting syndrome and mortality in a dose range up to 80 mg/kg per day, whereas a dose of 160 mg/kg per day induced reversible side-effects.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 82410-32-0
Appearance Solid
Molecular Weight 255.23
Formel C₉H₁₃N₅O₄
Color White to off-white
SMILES

O=C1NC(N)=NC2=C1N=CN2COC(CO)CO
Synonyms

BW 759; 2'-Nor-2'-deoxyguanosine
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (28)

All Bio/Physico-chemical AssayOthersMicrobiological AssayCell Proliferation/Viability AssayIF

Sort by:

Journal Impact Factor

Cell

Synonymous mutations promote tumorigenesis by disrupting m6A-dependent mRNA metabolism. [Abstract]

2025 Apr 3;188(7):1828-1841.e15. PMID: 39952247
Cell

Defining the Teratoma as a Model for Multi-lineage Human Development. [Abstract]

2020 Nov 25;183(5):1402-1419.e18. PMID: 33152263

Ganciclovir purchased from MedChemExpress. Usage Cited in: Cell. 2020 Nov 25;183(5):1402-1419.e18. [Abstract]

In vivo studies of miR-124-HSV-tk-GFP teratomas in the presence of GCV administration (80mg/kg/d, 10 weeks) using both intratumoral (IT) and intratumoral and intraperitoneal injection methods. A heatmap showing cell type fraction log fold-change for each teratoma replicate compared to a control miR-124-HSV-tk-GFP teratoma in the absence of GCV. Z-scores for each cell type fraction change are plotted as well, with standard deviations calculated using a pooled variance.
Nat Neurosci

Spatiotemporally selective astrocytic ATP dynamics encode injury information sensed by microglia following brain injury in mice. [Abstract]

2024 Aug;27(8):1522-1533. PMID: 38862791
Nat Commun

Engineering a synthetic gene circuit for high-performance inducible expression in mammalian systems. [Abstract]

2024 Apr 17;15(1):3311. PMID: 38632224
Trends Biotechnol

Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system. [Abstract]

2025 Aug 29:S0167-7799(25)00316-6. PMID: 40885669
J Nanobiotechnology

GRP75-driven, cell-cycle-dependent macropinocytosis of Tat/pDNA-Ca2+ nanoparticles underlies distinct gene therapy effect in ovarian cancer. [Abstract]

2022 Jul 20;20(1):340. PMID: 35858873

Ganciclovir purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 Jul 20;20(1):340. [Abstract]

Long-term GCV (50 mg/kg, ip)-trigged nanoparticle-based therapy in ovarian cancer model.
Brain Behav Immun

Conditional ablation of reactive astrocytes to dissect their roles in spinal cord injury and repair. [Abstract]

2019 Aug:80:394-405. PMID: 30959174
Sci Data

High-content, arrayed compound screens with rhinovirus, influenza A virus and herpes simplex virus infections. [Abstract]

2022 Oct 8;9(1):610. PMID: 36209289

Ganciclovir purchased from MedChemExpress. Usage Cited in: Sci Data. 2022 Oct 8;9(1):610. [Abstract]

Exemplary overviews of one screening plate for each virus screen. Individual images of each well were stitched yielding the overviews. First two columns of each plate contained DMSO control solvent, the following 20 columns PCL compounds, and the last two columns the positive controls (BafA1 for RV and IAV, and GCV (25 μM) for HSV-1). Scale bar represents 10 mm.
Biochem Pharmacol

Ganciclovir attenuates the onset and progression of experimental autoimmune uveitis by inhibiting infiltration of Th17 and inflammatory cells into the retina. [Abstract]

2022 Mar:197:114917. PMID: 35041813
Pharmaceutics

Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers. [Abstract]

2023 Nov 27;15(12):2680. PMID: 38140021

Ganciclovir purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Nov 27;15(12):2680. [Abstract]

GCV (1-30 μM) exhibited a dose-dependent decrease in newly synthesized DNA due to its inhibitory impact on the viral polymerase processing activity.
Cells

The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation. [Abstract]

2019 Dec 20;9(1):31. PMID: 31861948

Ganciclovir purchased from MedChemExpress. Usage Cited in: Cells. 2019 Dec 20;9(1):31. [Abstract]

Antiviral effects of eltrombopag in combination with Ganciclovir (0.61-10000 nM). Effects of equimolar drug concentrations on HCMV LA expression in HCMV Hi91 (MOI 0.02) HFFs 120 h post infection. * p < 0.05 compared to either single treatment.
Microchem J

2021, 106587.
PLoS Pathog

Palmitoylation of KSHV pORF55 is required for Golgi localization and efficient progeny virion production. [Abstract]

2024 Apr 16;20(4):e1012141. PMID: 38626263
Pharmaceuticals (Basel)

New Assay Systems to Characterize the Broad-Spectrum Antiherpesviral and Non-Herpesviral Activity of Cyclin-Dependent Kinase (CDK) 8 Inhibitors. [Abstract]

2025 Oct 16;18(10):1560. PMID: 41155676
Eur J Pharm Sci

FRET-based assay using a three-way junction DNA substrate to identify inhibitors of human cytomegalovirus pUL89 endonuclease activity. [Abstract]

2019 Jan 15:127:29-37. PMID: 30342172

Ganciclovir purchased from MedChemExpress. Usage Cited in: Eur J Pharm Sci. 2019 Jan 15:127:29-37. [Abstract]

Viral reporter GFP expression after inoculation and compound treatment. Infected cells treated with DMSO control, BIO, Ganciclovir (GCV) or Letermovir (LTR)
J Gen Virol

Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection. [Abstract]

2026 Mar;107(3):002248. PMID: 41849209
Antiviral Res

Valspodar limits human cytomegalovirus infection and dissemination. [Abstract]

2021 Sep:193:105124. PMID: 34197862
J Virol

Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage. [Abstract]

2017 Jan 18;91(3). pii: e02152-16. PMID: 27881652
Stem Cells

Transcriptomic analysis of the m6A reader YTHDF2 in the maintenance and differentiation of human embryonic stem cells. [Abstract]

2025 Jun 24;43(7):sxaf032. PMID: 40418739
Microb Pathog

mTORC2-dependent autophagy inhibition regulates the replication of HSV-1 and adenovirus in viral keratitis & conjunctivitis. [Abstract]

2026 Apr:213:108349. PMID: 41628839
Am J Physiol Gastrointest Liver Physiol

Regulatory T cells are induced by gut microbiota through differentially regulating costimulatory molecules of enteric glial cells. [Abstract]

2026 May 1;330(5):G532-G548. PMID: 41711540
Pharmacol Res Perspect

Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats. [Abstract]

2020 Apr;8(2):e00575. PMID: 32266794
bioRxiv

2026 Jun 2.
New York University

2026.
Preprints

2025 Dec 2.
bioRxiv

Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene Therapy. [Abstract]

2025 Nov 13:2025.11.11.687828. PMID: 41293016
bioRxiv

2023 Sep 20.
Research Square Print

2023 Mar.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 60 mg/mL (235.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1.67 mg/mL (6.54 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9180 mL

19.5899 mL

39.1797 mL

5 mM

0.7836 mL

3.9180 mL

7.8359 mL

10 mM

0.3918 mL

1.9590 mL

3.9180 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (8.15 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (8.15 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 3.33 mg/mL (13.05 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597-638. [Content Brief]

[2]. Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [Content Brief]

[3]. Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115. [Content Brief]

[4]. Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12. [Content Brief]

[5]. Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4. [Content Brief]

[6]. Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39(3):189-197. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.9180 mL	19.5899 mL	39.1797 mL	97.9493 mL
H₂O / DMSO	5 mM	0.7836 mL	3.9180 mL	7.8359 mL	19.5899 mL
DMSO	10 mM	0.3918 mL	1.9590 mL	3.9180 mL	9.7949 mL
	15 mM	0.2612 mL	1.3060 mL	2.6120 mL	6.5300 mL
	20 mM	0.1959 mL	0.9795 mL	1.9590 mL	4.8975 mL
	25 mM	0.1567 mL	0.7836 mL	1.5672 mL	3.9180 mL
	30 mM	0.1306 mL	0.6530 mL	1.3060 mL	3.2650 mL
	40 mM	0.0979 mL	0.4897 mL	0.9795 mL	2.4487 mL
	50 mM	0.0784 mL	0.3918 mL	0.7836 mL	1.9590 mL
	60 mM	0.0653 mL	0.3265 mL	0.6530 mL	1.6325 mL
	80 mM	0.0490 mL	0.2449 mL	0.4897 mL	1.2244 mL
	100 mM	0.0392 mL	0.1959 mL	0.3918 mL	0.9795 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Ganciclovir

28 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ganciclovir

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Ganciclovir

Alle HSV Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (28)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ganciclovir Related Classifications

HY-13637 Related Classifications